Bal Pharma Ltd
As of 20 Nov 2026, Bal Pharma is in Stage 3, the topping phase, now in week 2 (since 13 Nov 2026). It closed at ₹83.21, 27.3% below its 52-week high and below its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. More about the company
Pro read
ProBALPHARMA's uptrend is tiring: 2 weeks into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.
Its relative strength is 69 of 99, above the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.
Is BALPHARMA early, or has it already run? Pro answers that for every NSE stock, after every close.
BALPHARMA among Pharmaceuticals61st of 118 by relative strength
All 118 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | BLISSGVS | Stage 2 · wk 49 | 99 | +4.6% |
| 2 | KPL | Stage 2 · wk 44 | 99 | +20.5% |
| 3 | FREDUN | Stage 2 · wk 33 | 98 | +24.0% |
| 4 | VENUSREM | Stage 3 · wk 10 | 98 | −1.5% |
| 5 | RUBICON | Stage 3 · wk 4 | 98 | +18.7% |
| 6 | SAKAR | Stage 2 · wk 55 | 98 | +13.1% |
| 7 | BAFNAPH | Stage 2 · wk 23 | 98 | +1.9% |
| 8 | INDSWFTLAB | Stage 2 · wk 23 | 98 | −7.4% |
| …61 | BALPHARMA | Stage 3 · wk 2 | 69 | −4.7% |
Bal Pharma: quick answers
What stage is Bal Pharma in?
As of 20 Nov 2026, Bal Pharma (BALPHARMA) is in Stage 3, the topping phase. It entered Stage 3 on 13 Nov 2026 and is in week 2. What the four stages mean
Is Bal Pharma in an uptrend?
Its uptrend has stalled. Bal Pharma is in Stage 3, the topping phase that follows an advance. It trades 0.5% below its 200-day average, which is rising.
How far is Bal Pharma from its 52-week high?
Bal Pharma closed at ₹83.21 on 20 Nov 2026, 27.3% below its 52-week high of ₹114. Its 52-week low is ₹60.42.
How has Bal Pharma performed over the past year?
As of 20 Nov 2026, Bal Pharma is up 4.1% over the past year and up 13.5% so far in 2026.
Which sector and industry is Bal Pharma in?
Bal Pharma is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals
About this companyHealth Care· Pharmaceuticals
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.